<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Interplay between Non-Coding RNAs and NRF2 in Different Cancers: Spotlight on MicroRNAs and Long Non-Coding RNAs

dc.contributor.authorYaylim, Ilhan
dc.contributor.authorFarooqi, Ammad Ahmad
dc.contributor.authorTelkoparan-Akillilar, Pelin
dc.contributor.authorSaso, Luciano
dc.date.accessioned2026-10-09T21:50:17Z
dc.date.issued2023
dc.departmentYüksek İhtisas Üniversitesi
dc.description.abstractCancer is a multifactorial disease, and a wealth of information has enabled basic and clinical researchers to develop a better conceptual knowledge of the highly heterogeneous nature of cancer. Deregulations of spatio-temporally controlled transduction pathways play a central role in cancer progression. NRF2-driven signaling has engrossed significant attention because of its fundamentally unique features to dualistically regulate cancer progression. Context-dependent diametrically opposed roles of NRF2-induced signaling are exciting. More importantly, non-coding RNA (ncRNA) mediated regulation of NRF2 and interplay between NRF2 and ncRNAs have added new layers of complexity to already intricate nature of NRF2 signaling. There is a gradual enrichment in the existing pool of knowledge related to interplay between microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) in different cancers. However, surprisingly, there are no clues about interplay between circular RNAs and NRF2 in various cancers. Therefore, future studies must converge on the functional characterization of additional important lncRNAs and circular RNAs, which regulated NRF2-driven signaling or, conversely, NRF2 transcriptionally controlled their expression to regulate various stages of cancer.
dc.identifier.doi10.1124/jpet.121.000921
dc.identifier.endpage34
dc.identifier.issn0022-3565
dc.identifier.issn1521-0103
dc.identifier.issue1
dc.identifier.orcid0000-0003-4530-8706
dc.identifier.orcid0000-0003-2899-5014
dc.identifier.pmid35667688
dc.identifier.scopus2-s2.0-85144591117
dc.identifier.scopusqualityQ2
dc.identifier.startpage28
dc.identifier.urihttps://doi.org/10.1124/jpet.121.000921
dc.identifier.urihttps://hdl.handle.net/20.500.12794/3733
dc.identifier.volume384
dc.identifier.wosWOS:000928423000004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.digerScience Citation Index Expanded (SCI-EXPANDED)
dc.language.isoen
dc.publisherAmer Soc Pharmacology Experimental Therapeutics
dc.relation.ispartofJournal of Pharmacology and Experimental Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.relation.sdgGoal-03: Good Health and Well-Being
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260922
dc.subjectTranscription Factor Nrf2
dc.subjectLncrna Tug1
dc.subjectProgression
dc.subjectExpression
dc.subjectResistance
dc.subjectSignature
dc.subjectCarcinoma
dc.subjectCells
dc.titleInterplay between Non-Coding RNAs and NRF2 in Different Cancers: Spotlight on MicroRNAs and Long Non-Coding RNAs
dc.typeReview Article

Files